Alternative Data for Esperion Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 30 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 365 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,186 | Sign up | Sign up | Sign up |
| X Followers | 2,121 | Sign up | Sign up | Sign up |
| X Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 45 | Sign up | Sign up | Sign up |
| Linkedin Employees | 338 | Sign up | Sign up | Sign up |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Price | $3.12 |
| Target Price | Sign up |
| Volume | 9,087,972 |
| Market Cap | $806M |
| Year Range | $1.91 - $4.08 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Drug Manufacturers |
In the news
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their ShareholdersMay 6 - GlobeNewswire |
|
 |
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQHMay 6 - PRNewswire |
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)May 5 - GlobeNewswire |
|
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKCMay 5 - GlobeNewswire |
|
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ:Â ESPR)May 1 - GlobeNewswire |
|
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic AgreementsMarch 4 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 80M | 0 | 0 | -25M | -6.6M | |
| Q4 '25 | 168M | 28M | 141M | 62M | 85M | 0.220 |
| Q3 '25 | 87M | 55M | 32M | -31M | -9.3M | -0.160 |
| Q2 '25 | 82M | 29M | 54M | -13M | 7.8M | -0.060 |
| Q1 '25 | 65M | 32M | 33M | -40M | -21M | -0.206 |
Insider Transactions View All
| Halladay Benjamin filed to sell 713,602 shares at $2.7. March 18 '26 |
| Looker Benjamin filed to sell 679,348 shares at $2.7. March 18 '26 |
| Koenig Sheldon L. filed to sell 2,172,699 shares at $2.7. March 18 '26 |
| Looker Benjamin filed to sell 384,216 shares at $2.9. January 21 '26 |
| Looker Benjamin filed to sell 385,905 shares at $3.7. December 18 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$230.42 2.7% | 55 |
 |
Eli Lilly and CompanyLLY |
$1015.75 2.6% | 72 |
 |
PfizerPFE |
$25.96 0.3% | 31 |
 |
AstrazenecaAZN |
$187.72 1.7% | 56 |
 |
AbbVieABBV |
$208.5 0.3% | 50 |
Read more about Esperion Therapeutics (ESPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Esperion Therapeutics
The Market Cap of Esperion Therapeutics is $806M.
Currently, the price of one share of Esperion Therapeutics stock is $3.12.
The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
